Agenus wins first marketing authorizations for BOT+BAL in Armenia

Agenus said Armenia granted its first marketing authorizations for botensilimab plus balstilimab in previously treated MSS metastatic colorectal cancer without active liver metastases. The conditional approvals run for one year from Oct. 2, 2026.